Infasurf Aero™
Combination ProductA single dose of Calfactant administered by pacifier interface by inhalation via the Infasurf Aero nebulizer at 6ml/kg.
NCT Number: NCT05960929
The purpose of this clinical study is to determine the effectiveness and safety of Infasurf® administered through the InfasurfAero™, a novel oral airway delivery device specifically designed to give Infasurf in a less complicated way and without the need for a breathing tube or interrupting nasal respiratory support.
Interested in participating?
Request Info29 week–36 week
All sexes
Interventional
Phase 3
Phoenix Children's, Phoenix, Arizona, United States
This single-dose, double-blind, random allocation, sham-control, clinical trial will recruit spontaneously breathing newborns with RDS stable on non-invasive nasal respiratory support. Enrolled clinical study subjects will be randomly allocated to receive respiratory air with Infasurf® (Intervention Arm) or respiratory air alone (Sham Control Arm) through the InfasurfAero™.
The objectives of this clinical study are to i) assess the effectiveness of a single dose of Infasurf administered through the InfasurfAero in preventing CPAP failure, and ii) assess the safety of Infasurf administered through the InfasurfAero.
Subjects will be enrolled at one of 10+ sites. 7 sites are currently recruited.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
include ALL of the following:
Exclusion criteria
Exclusion criteria
are ANY of the following:
A single dose of Calfactant administered by pacifier interface by inhalation via the Infasurf Aero nebulizer at 6ml/kg.
Time frame: Within 1st week of age
CPAP failure is defined as a respiratory severity score (RSS) (MAP x FiO2) >2.5 on two consecutive assessments at least 30 minutes apart, or an RSS > 2.4 and one or more of the following:
(i) Silverman-Andersen respiratory severity score (https://www.thecalculator.co/health/Silverman-Score-Calculator-1125.html) of ≥ 5 despite respiratory support.
(ii) Severe apnea (2 or more episodes per hour, or 1 or more episodes requiring manual positive pressure ventilation).
(iii) Respiratory acidosis (pCO2 > 65 with a pH < 7.2 on blood gas). RSS will be the primary indicator of CPAP failure. However with the addition of the Silverman-Anderson scores, severe apnea and respiratory acidosis, CPAP failure may occur earlier than solely defined by RSS score.
Time frame: 36 weeks post menstrual age (PMA).
Chronic lung disease is defined as altitude adjusted oxygen requirement at 36 weeks post menstrual age.
Time frame: 36 weeks PMA
Incidence of Mechanical Ventilation
Time frame: 36 weeks PMA
length of time of Mechanical Ventilation
Time frame: 36 weeks PMA
Any occurrence of tracheal intubation
Time frame: 72 hours post birth
any occurrence of liquid surfactant administration via and endotracheal tube
Time frame: 36 weeks PMA
Length of time of respiratory support other than Intubation
Time frame: 36 weeks PMA
Length of time any oxygen is administered.
Time frame: Birth to 72 hours of age.
Incidence of bradycardia and desaturation during surfactant administration.
Contact information is provided by the study sponsor or research team.
Corey Commaroto, RRT
CONTACT
Dan Swartz, PhD
CONTACT
ONY
Industry
InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS: A Single-dose, Double-blind, Random Allocation, Sham-control, Clinical Trial
Acronym: Aero-05
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07550218
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases and Pregnancy Complications
View Trial DetailsNCT07237139
Chronic Lung Disease of Newborn, Female Urogenital Diseases and Pregnancy Complications
Zurich, Canton of Zurich, Switzerland
View Trial DetailsNCT07418502
BPD - Bronchopulmonary Dysplasia, Bronchopulmonary Dysplasia
San Diego, California, United States
View Trial DetailsNCT07426016
Lung Diseases, Pulmonary Atelectasis
Dallas, Texas, United States
View Trial Details